CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
23 déc. 2024 08h01 HE
|
Corxel Pharmaceuticals
CORXEL expands its cardiometabolic pipeline into obesity and diabetes.
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
10 déc. 2024 08h00 HE
|
RENAISSTHERA PRIVATE LIMITED
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
09 déc. 2024 22h30 HE
|
RENAISSTHERA PRIVATE LIMITED
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
e-therapeutics Announces Business Updates and Interim Results
31 oct. 2024 09h00 HE
|
e-therapeutics plc
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024
30 août 2024 08h00 HE
|
Imbria Pharmaceuticals Inc.
– Ninerafaxstat was well tolerated and showed no impact on systemic hemodynamics in patients with stable angina and chronic coronary syndrome – – These findings support a direct,...
Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
25 mars 2024 08h00 HE
|
Imbria Pharmaceuticals Inc.
– Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete;Phase 3 to be initiated in the 2H 2024 – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Imbria...
Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health
09 nov. 2023 08h00 HE
|
Cardiometabolic Health Congress
Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now...
Patient-Focused Next Generation Home Blood Test for Cardiometabolic Health Now Available to Consumers
28 août 2023 12h08 HE
|
CardioMetaboliQ LLC
—An alarming 93 percent of US adults have less than optimal cardiometabolic health1 and many are completely unaware of their risk— —New test provides end-to-end cardiometabolic health solution, with...
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
16 août 2023 08h00 HE
|
Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
17 mai 2023 08h00 HE
|
Imbria Pharmaceuticals Inc.
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...